Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged \>=10 and \<26 years at the time of enrollment.~* Healthy subject as determined by medical history, physical examination, and judgment of the investigator.~* Negative urine pregnancy test for all female subjects.~* Subjects who have not received, or who have received no more than 1 prior dose within the past 4 years, of a vaccine containing 1 or more ACWY serogroup~Exclusion Criteria:~* Previous vaccination with any meningococcal serogroup B or purely polysaccharide (nonconjugate) meningococcal vaccine.~* Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.~* A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.~* Significant neurological disorder or history of seizure (excluding simple febrile seizure).~* Current chronic use of systemic antibiotics.~* Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.~* Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (ACWY Naive subjects, MenABCWY/Saline) (Type: EXPERIMENTAL): ACWY Naive subjects, MenABCWY/Saline
- Group 2 (ACWY Naive subjects, rLP2086/MenACWY-CRM) (Type: EXPERIMENTAL): ACWY Naive subjects, rLP2086/MenACWY-CRM
- Group 3 (ACWY Experienced subjects, MenABCWY/Saline) (Type: EXPERIMENTAL): ACWY Experienced subjects, MenABCWY/Saline
- Group 4 (ACWY Experienced subjects, rLP2086/MenACWY-CRM) (Type: EXPERIMENTAL): ACWY Experienced subjects, rLP2086/MenACWY-CRM

Based on this trial design, predict the completion outcome and termination type (if applicable).